Back to Blogs
The Bounce Back for Life Sciences: What to Expect in 2025
The Bounce Back for Life Sciences: What to Expect in 2025
Company newsIndustry intelligenceAuthor: James Cox
BioTalent CEO James Cox shared his thoughts on the life sciences market, highlighting a promising rebound ahead. After a few challenging years marked by subdued M&A activity, record layoffs, and reduced investor confidence, the industry is gearing up for a major M&A surge in 2025. This is driven by pent-up demand, record-high dry powder, and a growing performance gap between industry leaders and laggards. New technologies and a shift in R&D focus away from oncology are creating new opportunities.
Here’s what BioTalent has been observing as we connect with VCs, PEs, and thought leaders:
M&A trends and key insights
- Deal volume down in 2024: life sciences M&A dropped by 24%, returning to 2022 levels.
- Private equity rebound: PE-backed deals rose from 11% in 2023 to 15% in 2024, signalling renewed investor confidence.
- Sector breakdown: biotech (44%) and pharma (28%) dominate, driven by strong demand for pipeline expansion.
- MedTech growth: MedTech saw the second-highest volume of billion-dollar deals in a decade, with digital health and innovation at the forefront.
- Life science services surge: the sector is gaining momentum as companies seek integrated solutions, with outsourcing set to grow at a 28% CAGR until 2030.
- Cross-border M&A rise: global expansion is on the rise, though trade wars could impact cross-regional deals in 2025.
What’s ahead for 2025?
The M&A landscape is evolving, and companies are preparing for:
- Pipeline reinforcement: with over 50% of biopharma revenues at risk of losing exclusivity by 2027, the urgency for acquisitions will increase.
- High deal premiums: companies are paying more for strategic acquisitions, which may put pressure on integration and value creation.
- MedTech and biotech consolidation: 80% of deals are growth-focused acquisitions, up from 34% a decade ago.
What does this mean for talent?
As M&A strategies ramp up, the demand for specialised talent is heating up in R&D, AI/ML, Computational, Automation, Quality, Engineering, and more. BioTalent is here to connect the brightest minds with the most innovative companies, driving forward Industry 4.0.
Get in touch with the BioTalent Team
Flexible hiring, built around how your business actually scales. To discuss your next hire, project or workforce need, speak to the BioTalent team.
Part of
NPS Score
70+ is considered world-class
76
Get in touch
Whether you're hiring or job hunting, we're here to make the process simple. Reach out and let's talk.
All Rights Reserved 2026 BioTalent
Site by